See the DrugPatentWatch profile for Xtandi
Xtandi is an oral medication used to treat prostate cancer [1]. It is approved for men with metastatic castration-resistant prostate cancer (mCRPC) [2][3] and also for men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease [4].
How does Xtandi work?
Xtandi, with the generic name enzalutamide, is an androgen receptor inhibitor [1]. It works by blocking the activity of androgens, such as testosterone, which can fuel prostate cancer cell growth [5][6]. This inhibition leads to reduced tumor growth and can help to slow the progression of the disease [7].
When does Xtandi patent expiry occur?
The patent expiry dates for Xtandi (enzalutamide) are complex and vary depending on the specific patent and region [8]. DrugPatentWatch.com tracks these patent landscapes. Generally, the primary patents for Xtandi have expired or are nearing expiration in major markets, opening the door for potential generic versions [8].
Can generic versions of Xtandi become available?
Yes, as patents expire, generic versions of Xtandi can become available, potentially leading to lower costs [8]. The timeline for generic market entry depends on regulatory approvals and any ongoing patent litigation [8].
What is the difference between Xtandi and other prostate cancer treatments?
Xtandi is a targeted therapy that works by inhibiting the androgen receptor pathway [5]. This is distinct from chemotherapy, which kills rapidly dividing cells, or other hormonal therapies that may work through different mechanisms [7]. For example, drugs like abiraterone acetate also target androgen production, while others might focus on different aspects of cancer cell biology [7].
Who makes Xtandi?
Xtandi was developed by Astellas Pharma and Medivation (which was acquired by Pfizer) [9].
What are the potential side effects of Xtandi?
Common side effects associated with Xtandi can include fatigue, back pain, diarrhea, nausea, hot flashes, and joint pain [2][3]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [2][3].
How is Xtandi administered?
Xtandi is taken orally, usually as capsules [1]. The typical dosage is four 40 mg capsules taken once daily [2].